Key facts
- This page summarizes Vered Bisker-Leib's Form 4 filing for Compass Therapeutics, Inc. (CMPX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 10 Jan 2024, 10:31.
Vered Bisker-Leib - 09 Jan 2024 Form 4 Insider Report for Compass Therapeutics, Inc. (CMPX)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- CMPX
- Reported as of
- 09 Jan 2024
- Net transaction value
- +$3,383,531
- SEC form
- 4
- Accepted by SEC
- 10 Jan 2024, 10:31:46 UTC
- Prior SEC filing
- 21 Nov 2023
- Next SEC filing
- 09 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Vered Bisker-Leib
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Vered Bisker-Leib filed Form 4 for Compass Therapeutics, Inc. (CMPX) on 10 Jan 2024.
Change
- Previous filing in this sequence was filed on 21 Nov 2023.
- Current net transaction value: +$3,383,531.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CMPX
transaction
Common Stock
Award
- Transaction value
- $3,383,531
- Shares
- +1,753,125
- Change %
- +123%
- Price
- $1.93
- Shares after
- 3,173,624
- Date
- 09 Jan 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CMPX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +1,753,125
- Change %
- Price
- $0.000000
- Shares after
- 1,753,125
- Date
- 09 Jan 2024
- Ownership
- Direct
- Underlying class
- CommonStock
- Underlying amount
- 1,753,125
- Exercise price
- $1.93
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents restricted stock units ("RSU") granted to the reporting person on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on January 9, 2025.
Footnote F2
300,000 of the shares represents unvested restricted stock units ("RSU") granted on November 16, 2021. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022. 400,000 of the shares represents unvested restricted stock units ("RSU") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 1,753,125 of the shares represents unvested restricted stock units ("RSU") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025.
Footnote F3
The options vest over 48 substantially equal monthly installments starting February 9, 2024.